Satralizumab, Satralizumab
WN41733
Phase 3 small_molecule active
Quick answer
Satralizumab, Satralizumab for Neuromyelitis Optica Spectrum Disorder (NMOSD) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active